E
Acumen Pharmaceuticals, Inc.
ABOS
$0.988
-$0.092-8.52%
E
Sell
3/7/2025Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 3/7/2025 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 48.66% from -$16.55M to -$24.6M, earnings per share declined from -$0.3418 to -$0.4954, and EBIT declined 32.34% from -$24.38M to -$32.27M.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 3/7/2025 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 48.66% from -$16.55M to -$24.6M, earnings per share declined from -$0.3418 to -$0.4954, and EBIT declined 32.34% from -$24.38M to -$32.27M.
D
Sell
10/4/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 10/4/2024 due to an increase in the volatility index and total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 10/4/2024 due to an increase in the volatility index and total return index.
E
Sell
9/19/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 9/19/2024 due to a decline in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 9/19/2024 due to a decline in the volatility index.
D
Sell
8/30/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/30/2024 due to an increase in the volatility index and total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/30/2024 due to an increase in the volatility index and total return index.
E
Sell
8/15/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 8/15/2024 due to a decline in the volatility index, growth index and solvency index. The quick ratio declined from 29.83 to 16.96, earnings per share declined from -$0.2487 to -$0.3418, and EBIT declined 37.17% from -$17.77M to -$24.38M.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 8/15/2024 due to a decline in the volatility index, growth index and solvency index. The quick ratio declined from 29.83 to 16.96, earnings per share declined from -$0.2487 to -$0.3418, and EBIT declined 37.17% from -$17.77M to -$24.38M.
D
Sell
8/2/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/2/2024 due to an increase in the volatility index and total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/2/2024 due to an increase in the volatility index and total return index.
E
Sell
7/17/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 7/17/2024 due to a decline in the volatility index, total return index and valuation index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 7/17/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
6/27/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 6/27/2024 due to an increase in the volatility index and valuation index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 6/27/2024 due to an increase in the volatility index and valuation index.
E
Sell
6/10/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 6/10/2024 due to a decline in the volatility index and total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 6/10/2024 due to a decline in the volatility index and total return index.
D
Sell
5/21/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 5/21/2024 due to an increase in the volatility index and total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 5/21/2024 due to an increase in the volatility index and total return index.
E
Sell
5/3/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index, total return index and growth index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
4/18/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 4/18/2024 due to an increase in the volatility index and valuation index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 4/18/2024 due to an increase in the volatility index and valuation index.
E
Sell
3/28/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 3/28/2024 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.2389 to -$0.2866, and EBIT declined 15.26% from -$16.04M to -$18.49M.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 3/28/2024 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.2389 to -$0.2866, and EBIT declined 15.26% from -$16.04M to -$18.49M.
D
Sell
3/11/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 3/11/2024 due to an increase in the volatility index and total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 3/11/2024 due to an increase in the volatility index and total return index.
E
Sell
2/22/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 2/22/2024 due to a decline in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 2/22/2024 due to a decline in the volatility index.
D
Sell
2/2/2024Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index.
E
Sell
1/17/2024Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 1/17/2024 due to a decline in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 1/17/2024 due to a decline in the volatility index.
D
Sell
12/27/2023Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index.
E
Sell
12/8/2023Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 12/8/2023 due to a decline in the volatility index and total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 12/8/2023 due to a decline in the volatility index and total return index.
D
Sell
11/20/2023Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 11/20/2023 due to a noticeable increase in the growth index, solvency index and volatility index. The quick ratio increased from 17.01 to 35.36, and earnings per share increased from -$0.283 to -$0.2389.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 11/20/2023 due to a noticeable increase in the growth index, solvency index and volatility index. The quick ratio increased from 17.01 to 35.36, and earnings per share increased from -$0.283 to -$0.2389.
E
Sell
11/3/2023Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 11/3/2023 due to a decline in the total return index, volatility index and growth index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 11/3/2023 due to a decline in the total return index, volatility index and growth index.
D
Sell
9/14/2023Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 9/14/2023 due to an increase in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 9/14/2023 due to an increase in the volatility index.
E
Sell
8/30/2023Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index.
D
Sell
8/14/2023Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index, total return index and valuation index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/1/2023Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 8/1/2023 due to a decline in the total return index, volatility index and growth index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 8/1/2023 due to a decline in the total return index, volatility index and growth index.
D
Sell
7/17/2023Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 7/17/2023 due to a noticeable increase in the total return index and volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 7/17/2023 due to a noticeable increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
E
Sell
2/8/2023Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index, total return index and valuation index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
1/30/2023Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to D- from D on 1/30/2023 due to a decline in the total return index and volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to D- from D on 1/30/2023 due to a decline in the total return index and volatility index.
D
Sell
1/13/2023Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D from D- on 1/13/2023 due to an increase in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D from D- on 1/13/2023 due to an increase in the volatility index.
D
Sell
12/27/2022Downgrade
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to D- from D on 12/27/2022 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 41.98% from -$6.47M to -$9.18M, the quick ratio declined from 37.02 to 30.29, and EBIT declined 9.22% from -$10.41M to -$11.37M.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to D- from D on 12/27/2022 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 41.98% from -$6.47M to -$9.18M, the quick ratio declined from 37.02 to 30.29, and EBIT declined 9.22% from -$10.41M to -$11.37M.
D
Sell
9/15/2022Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D from D- on 9/15/2022 due to an increase in the total return index and volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D from D- on 9/15/2022 due to an increase in the total return index and volatility index.
D
Sell
8/16/2022Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/16/2022 due to a large increase in the growth index, solvency index and volatility index. Operating cash flow increased 22.06% from -$8.3M to -$6.47M.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to D- from E+ on 8/16/2022 due to a large increase in the growth index, solvency index and volatility index. Operating cash flow increased 22.06% from -$8.3M to -$6.47M.
E
Sell
4/1/2022Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to E+ from E on 4/1/2022 due to an increase in the volatility index.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to E+ from E on 4/1/2022 due to an increase in the volatility index.
E
Sell
1/3/2022Upgraded
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to E from E- on 1/3/2022 due to a significant increase in the solvency index, efficiency index and growth index. The quick ratio increased from 15.25 to 134.37, total capital increased 241.04% from $68.43M to $233.36M, and earnings per share increased from -$141.9256 to -$0.102.
Acumen Pharmaceuticals, Inc. (ABOS) was upgraded to E from E- on 1/3/2022 due to a significant increase in the solvency index, efficiency index and growth index. The quick ratio increased from 15.25 to 134.37, total capital increased 241.04% from $68.43M to $233.36M, and earnings per share increased from -$141.9256 to -$0.102.
E
Sell
9/24/2021None
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E- from U on 09/24/2021.
Acumen Pharmaceuticals, Inc. (ABOS) was downgraded to E- from U on 09/24/2021.
NASDAQ
04/03/2025 4:00PM Eastern
Quotes delayed
